Trinity Partners Launches New Products to Help Optimize the Commercialization Process for Biopharmaceutical Clients

Cornerstone projects provide best-in-class approaches to key challenges in the drug commercialization space

BOSTON--()--Trinity Partners, a global life sciences consulting firm, announced today that it has launched formalized products around six key areas of expertise focused on the necessary foundational work to support the successful commercialization of a product in today’s dynamic environment.

These pillar programs, termed Cornerstone projects, are based on proven approaches that the company has been employing for the past twenty years to assist biopharmaceutical clients in the process of activities such as expanding portfolios, gaining market insights, launching and/or pricing new products, and many more. These new products come at a challenging time for biopharmaceutical companies. In fact, according to a 2014 study by Tufts Center for the Study of Drug Development the cost to receive approval for just one drug is $2.6 billion USD.

The Cornerstone projects systematize Trinity’s best practices and multidisciplinary expertise to create a consistent work product so that clients know exactly what to expect when they work with Trinity on their strategic commercial engagements. Please see each project and its area of focus below:

  • TRek – Integrated patient journey research:
    A holistic, data-driven research tool that incorporates both claims analysis and primary market research to identify and characterize key leverage points in the patient journey.
  • TRailblazer – Analytical launch planning:
    A set of products offering a clearly defined analytical plan to optimize product value via sequencing and execution of critical pre-launch activities.
  • TRaject – Strategic forecasting:
    A gold-standard forecasting methodology centered on innovative, standardized forecasting solutions that provide transparent, actionable insights for our clients.
  • TaRget – Business development and licensing:
    A menu of tools optimized for integrated quick-turnaround BD assessments, including Trinity’s proprietary QuickQuant market research survey tool and forecast model.
  • OpTimizeR – Strategic pricing and reimbursement research:
    A strategic pricing research offering that applies a balanced, rational, and evidence-based approach, incorporating Trinity’s multidisciplinary research capabilities.
  • ConTRact – Contracting offerings:
    A comprehensive suite of specialized tools and methodologies to support a wide range of contracting projects for both medical benefit and pharmacy benefit products.

“At Trinity Partners we have always taken great pride in delivering innovative insights that enable our clients’ success via unique methods and tools,” said David Fitzhenry, Managing Partner at Trinity Partners. “We are excited to offer comprehensive compilations of our key learnings regarding the commercialization of a product in today’s shifting drug development landscape.”

To see more information on each of the Cornerstone projects, please click here:

Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click here: []


PAN Communications
Kathryn McMahon, 617-502-4300

Release Summary

Trinity Partners announced that it has launched formalized products around six key areas of expertise to help optimize the commercialization process for biopharmaceutical clients.


PAN Communications
Kathryn McMahon, 617-502-4300